SCHEMBL127374

SCHEMBL127374

Clc1nccc2occc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 1/20 0.46
HTR2C P28335 2/20 0.43
TRPA1 O75762 1/20 0.39
MAOA P21397 3/20 0.39
MAOB P27338 3/20 0.39
FTO Q9C0B1 1/20 0.39
LMNA P02545 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAPT P10636 1/20 0.38
APEX1 P27695 1/20 0.38
MAPK1 P28482 1/20 0.38
PMP22 Q01453 1/20 0.38
CNR2 P34972 1/20 0.36
DRD1 P21728 5/20 0.36
NFKB1 P19838 1/20 0.33
F2RL3 Q96RI0 1/20 0.33
AURKA O14965 1/20 0.32
KCNA3 P22001 1/20 0.32
DYRK1A Q13627 1/20 0.32
HTR2A P28223 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29615409 1.00 FADS1 (0.46) FADS1HTR2CTRPA1MAOAMAOB
SCHEMBL557772 0.73 NOS3 (0.43) FADS1HTR2CTRPA1MAOAMAOB
SCHEMBL11625851 0.73 HTR2C (0.43) FADS1HTR2CTRPA1MAOAMAOB
SCHEMBL22729154 0.73 HTR2C (0.43) FADS1HTR2CTRPA1MAOAMAOB
SCHEMBL16488517 0.73 HTR2C (0.43) FADS1HTR2CTRPA1MAOAMAOB
SCHEMBL15688333 0.73 HTR2C (0.43) FADS1HTR2CTRPA1MAOAMAOB
SCHEMBL2757287 0.73 HTR2C (0.47) FADS1HTR2CTRPA1CNR2DRD1
SCHEMBL22323315 0.73 TRPA1 (0.46) FADS1HTR2CTRPA1MAOAMAOB
SCHEMBL3803166 0.72 HTR2C (0.40) FADS1HTR2CTRPA1MAOAMAOB
SCHEMBL29935606 0.72 HTR2C (0.40) FADS1HTR2CTRPA1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 352 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222393-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2010-09-02 US claimed
US-20100004215-A1 COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-01-07 US claimed
US-12534474-B2 Dihydrofuropyridine derivatives as rho-kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-01-27 US disclosed
US-12522595-B2 Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2026-01-13 US disclosed
EP-4169575-B1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS SATO PHARMA (JP) 2026-01-07 EP disclosed
US-12404249-B2 Heterocyclic derivatives and use thereof C&C RESEARCH LABORATORIES (KR) 2025-09-02 US disclosed
EP-4263548-B1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARM SPA (IT) 2025-07-02 EP disclosed
EP-3802495-B1 4-(2-((2-CHLOROQUINOLIN-4-YL)AMINO)ETHYL)BENZENESULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER C&C RES LAB (KR) 2025-07-02 EP disclosed
EP-4263547-B1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARM SPA (IT) 2025-07-02 EP disclosed
US-20250114345-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-04-10 US disclosed
EP-4524135-A1 KINESIN KIF18A INHIBITOR AND USE THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2025-03-19 EP disclosed
US-4808595-A REDUCTION OF PRESSURE DUE TO GLAUCOMA MERCK & CO., INC. (US) 1989-02-28 US disclosed
EP-0271273-A2 Thieno-and furopyridine sulfonamides MERCK & CO. INC. (US) 1988-06-15 EP disclosed
US-4577014-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1986-03-18 US disclosed
US-4501739-A BACTERICIDES, ANTIBIOTICS ELI LILLY AND COMPANY (US) 1985-02-26 US disclosed
US-4406898-A ANTIBIOTICS CONTAINING A THIENOPYRIDINIUM OR FUROPYRIDINIUM GROUP ELI LILLY AND COMPANY (US) 1983-09-27 US disclosed
EP-0074268-A2 Improvements in or relating to thieno and furopyridinium-substituted cephalosporin derivatives ELI LILLY AND COMPANY (US) 1983-03-16 EP disclosed
WO-1981003493-A1 4-(1-PIPERAZINYL)-FURO(3,2C)PYRIDINE DERIVATIVES,PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME CERM CENT EUROP RECH MAUVERNAY (FR) 1981-12-10 WO disclosed
US-4071630-A ANGINA PECTORIS SANDOZ LTD. (CH) 1978-01-31 US disclosed
US-3941797-A ANTIANGINA, SHOCK SANDOZ, INC. (US) 1976-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222393-A1 MUSCARINIC RECEPTOR ANTAGONISTS CHRM3, CHRM2, CHRM1 FADS1 972/4885HTR2C 191/4885TRPA1 383/4885
US-12534474-B2 Dihydrofuropyridine derivatives as rho-kinase inhibitors ROCK1, RHOC, ROCK2 FADS1 3896/4885HTR2C 2103/4885TRPA1 3498/4885
US-20250114345-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF EP300, CREBBP, HDAC1 FADS1 1461/4885HTR2C 3500/4885TRPA1 3447/4885
US-12404249-B2 Heterocyclic derivatives and use thereof STAT3, JAK2, IRF3 FADS1 3585/4885HTR2C 3473/4885TRPA1 2747/4885
US-20100004215-A1 COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS PDE4B, PDE4A, PDE3B FADS1 2885/4885HTR2C 779/4885TRPA1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.